Having trouble accessing articles? Reset your cache.

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

Myriad misses Street as CEO Capone departs

Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting fiscal 2Q20 EPS and revenues that missed consensus estimates and announcing the departure of President and CEO Mark Capone. R. Bryan Riggsbee will serve as interim

Read the full 442 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE